AQST News and Press, Aquestive Therapeutics Inc. From 05/05/20

Continues to manufacture and deliver therapies and advance R&D efforts during COVID-19 pandemic  Expects to submit AQST-108 (epinephrine) IND by June 2020 and to commence PK trials by end of 2020 Continues to advance Libervant (diazepam) through FDA review proces...

Aquestive Therapeutics ( AQST ) has been a roller coaster investment over the past year, but 2020 is setting up to be a transformative year for the company and investors. The company laid the groundwork in 2019, with a pre-IND meeting for AQST-108, the FDA accepted Libervant’s NDA, and ...

Following objections over large publicly traded companies getting forgivable loans under the Payroll Protection Program, the U.S. Treasury issues new guidance explaining that the program is meant for companies with little access to other sources of capital, not for publicly traded companie...

Even with the U.S. Senate set to vote later today on passing an additional relief bill for small businesses in the U.S., there is a bright spotlight being thrown on where the funds from the original Paycheck Protection Program designed for small business went. More news on: Legacy Housing ...

WARREN, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it will repo...

Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +100% . More news on: Sonnet BioTherapeutics Holdings, Inc., MEI Pharma, Inc., NantKwest, Inc., Stocks on the move, Read more ...

Houston, Texas--(Newsfile Corp. - March 17, 2020) - ​Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that its Board of Directors has appointed Gregory B. Brown, MD, as Chief Executive Officer. He currently serves and will remain on th...

Image source: The Motley Fool. Aquestive Therapeutics, Inc.   (NASDAQ: AQST) Q4 2019 Earnings Call Mar 12, 2020 , 8:00 a.m. ET Operator Continue reading

Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Stephanie Carrington - Westwicke Investor Relations Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Conference Call Participants ...

Aquestive Therapeutics (NASDAQ: AQST ): Q4 GAAP EPS of -$0.48 misses by $0.10 . Revenue of $16.42M (-2.4% Y/Y) beats by $0.58M . Press Release More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,